TL;DR
People born with familial adenomatous polyposis grow hundreds of polyps in the colon, and those polyps turn cancerous. Recursion Pharmaceuticals says a daily pill, REC-4881, cut the total polyp burden in 13 of 15 patients after 12 weeks, about 87%, with a median drop of 47%, nearly half. In two patients, polyp counts fell from more than 90 to one. The company says its AI models helped point it to the way the drug works, blocking proteins called MEK1 and MEK2. That is the company's account, from a small trial with no placebo group, and a larger trial meant to support approval is planned for the second half of 2027. It is one more sign that drugs aimed with AI's help are now producing results in people, the step that decides whether AI can shorten the long road from idea to medicine. For our odds on when this pill could reach patients, and the timeline of AI-found medicines that leads there, subscribe.
Below the line, for paid subscribers: The full story: where it stands, how we got here and what's dated next; our labeled speculation on what it adds up to; and every source.